GLPGF News and Press, Galapagos Genomics Ord From 08/20/20

G1 Therapeutics receives FDA acceptance of its Small Cell Lung Cancer NDA G1 Therapeutics Inc. ( GTHX ) reported that the FDA has accepted its New Drug Application of its lead drug candidate, Trilaciclib. The FDA has given Priority Review status to the NDA, and the PDUFA action date has ...

Galapagos NV (GLPG) Q2 2020 Results Earnings Conference Call August 07, 2020, 08:00 AM ET Company Participants Elizabeth Goodwin - Investor Relations Onno van de Stolpe - Chief Executive Officer Piet Wigerinck - Chief Scientific Officer Walid Abi-Saab - Chief Medical Officer ...

Gilead ( GILD ) - first, the bear case GILD reported Q2 results Thursday. The stock, which had begun underperforming the sector ( IBB ), dropped further, and on a weak day for biotech Friday closed down 3.9% at $69.53. After having led the sector up this year, it is now lagging IBB's to...

Gilead Sciences (NASDAQ: GILD ) is one of the largest bio-pharmaceutical companies in the world with a market capitalization of roughly $90 billion. The company has performed admirably well since the start of the year due to investor excitement over Remdesivir, a potential COVID-19 treatment....

Quick Take Pliant Therapeutics ( PLRX ) intends to raise $90 million from the sale of its common stock in an IPO, plus another $10 million in a concurrent private placement, according to an amended registration statement . The company is developing treatments for fibrosis, cancer and othe...

Applied Genetic Reports Positive Preclinical Data for Eye Disorder Treatment Applied Genetic Technologies Corporation (AGTC) announced the results for its clinical trial related to X-Linked retinitis pigmentosa. The data provided the basis for determining the starting dose and the vector...

Background Yesterday, Gilead ( GILD ) and Galapagos ( GLPG ) finally released phase 3 results from their filgotinib trials in ulcerative colitis. Having followed the crowded space for novel ulcerative colitis and Crohn's disease agents very closely for many years, I think the results w...

The much-hated bull market is losing steam as optimism about a V-shaped recovery is making room for realism with headlines including 'Why the market could go much lower' and 'The US is risking a second COVID-19 wave'. On the contrary, we still have the Fed pumping unprecedented (my God, I l...

Background This is Part 2 of a 2-part set of articles about Gilead ( GILD ); Part 1 focused on its remdesivir ("RDV") for COVID-19. There is probably more going on at GILD than the focus on RDV in GILD's recent Q1 earnings report and conference call could allow to be discussed. The ...

Galapagos NV (GLPG) Q1 2020 Results Conference Call May 8, 2020 8:00 AM ET Company Participants Elizabeth Goodwin - Investor Relations Onno van de Stolpe - CEO Bart Filius - COO and CFO Piet Wigerinck - Chief Scientific Officer Walid Abi-Saab - Chief Medical Officer Miche...